Powder: -20°C for 3 years | In solvent: -80°C for 1 year
hCAIX-IN-12 是有效的hCAIX 抑制剂,抑制 CAIX 和 CAII 的IC50分别为 0.74 和 10.78 μM。hCAIX-IN-12 抗细胞增殖并诱导凋亡 (apoptosis)。hCAIX-IN-12 可以增加ROS 的产生。hCAIX-IN-12在结直肠癌(CRC)中具有研究潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | hCAIX-IN-12 is an effective hCAIX inhibitor, IC50 for CAIX and CAII is 0.74 and 10.78 μM , respectively. hCAIX-IN-12 inhibits cell proliferation and induces apoptosis. HCAIX-IN-12 can increase the generation of ROS. HCAIX-IN-12 has research potential in colorectal cancer (CRC). |
体外活性 | hCAIX-IN-12 (compound OX27) shows antiproliferative effect with IC 50 s of 6.0 μM for HCT-116 cells [1]. hCAIX-IN-12 decreases the expression of CAIX in HCT-116 cells and inhibits the expression of CAIX more pronouncedly in hypoxic conditions [1]. hCAIX-IN-12 (0-50 μM; 0-48 h) inhibits the colony formation in a dose-dependent manner and 7 inhibits the migration of HCT-116 cells [1]. hCAIX-IN-12 (6.0 μM; 48 h) induces apoptosis in HCT-116 cells [1]. hCAIX-IN-12 (6.0 μM; 24,48 h) increases in the levels of ROS in HCT-116 cells [1]. hCAIX-IN-12 causes depletion of HCT-116 cells in the G0/G1 (P2 65.21%) phase with an increase in the accumulation of cells in G2/M (P4 18.95%) phase [1]. hCAIX-IN-12 has high binding affinity for CAIX and substantial affinity for HSA [1]. |
分子量 | 398.46 |
分子式 | C18H14N4O3S2 |
CAS No. | 2414598-85-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
hCAIX-IN-12 2414598-85-7 Inhibitor inhibitor inhibit